Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus PHENYTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus PHENYTEX.
PARADIONE vs PHENYTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Also enhances GABA-mediated inhibition.
100 mg orally three times daily; maximum 600 mg/day.
300-400 mg/day orally in divided doses, typically 100 mg three times daily or 200 mg twice daily; loading dose 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) at 2-hour intervals, or 10-15 mg/kg IV at a rate not exceeding 50 mg/min.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
22 hours (range 7-42 hours; prolonged in hepatic impairment; clinical context: steady-state achieved in 5-7 days)
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Renal (hepatic metabolism to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal excretion minimal)
Category C
Category C
Anticonvulsant
Anticonvulsant